Read more

January 16, 2025
2 min read
Save

SGLT2 inhibitors may improve kidney outcomes for Asian adults with type 2 diabetes

Key takeaways:

  • Starting SGLT2 inhibitors led to a lower risk of eGFR decline or incident kidney failure.
  • SGLT2 inhibitors were also linked to reduced amputation and AKI risks.

Use of SGLT2 inhibitors was associated with improved kidney health among a diverse multiethnic cohort of Asian adults with type 2 diabetes, researchers found in a retrospective cohort study.

Diabetes is a “major contributor to the rising global burden of chronic kidney disease associated with significant morbidity, high mortality and reduced quality of life,” Liang Feng, PhD, a principal research scientist at the Duke-NUS Medical School program in health services and systems research in Singapore, wrote with colleagues. “Studies indicate Asian populations face an elevated risk of type 2 diabetes and accelerated progression to adverse vascular complications including CKD compared to their European counterparts.”

Scientist preparing a DNA sample for testing.
Starting SGLT2 inhibitors led to a lower risk of eGFR decline or incident kidney failure. Image: Adobe Stock.

Investigators used data from the SingHealth Diabetes Registry in Singapore to analyze the effects of SGLT2 inhibitors on kidney and safety outcomes in patients with type 2 diabetes in a clinical setting. Overall, 4,254 patients who started on SGLT2 inhibitors or other glucose-lowering medications from 2014 to 2018 were included: 2,127 patients were in each group.

Mean age of the cohort was 63.4 years; 48.6% of patients were women. Overall, 67.8% were Chinese; 11.9% were Indian; 15.6% were Malay; and the remaining 4.7% fell into other categories.

The composite kidney outcome included an eGFR decline of at least 40% or incident kidney failure with replacement therapy, rate of eGFR change, amputation and AKI.

Median follow-up was 25.6 months.

Starting SGLT2 inhibitors vs. no use of SGLT2 inhibitors was associated with a lower risk of the composite outcome (HR = 0.39; 95% CI, 0.31-0.48); and at least a 40% eGFR reduction from baseline (HR = 0.38; 95% CI, 0.31-0.48). SGLT2 inhibitor treatment was also linked to a reduced rate of eGFR decline, Feng and colleagues noted, with a difference in slope of 2.67 mL/min per 1.73 m² per year (95% CI, 1.9-3.43) among the 1,888 patients in the intention-to-treat population.

“In our study of a real-world cohort of multiethnic patients ... SGLT2 inhibitors had a sizeable protective effect on preserving kidney function but no association with amputation when compared with anti-diabetic regimens without SGLT2 inhibitors,” the researchers wrote. SGLT2 inhibitors also lowered AKI risk, but “more work needs to be done to optimize their utilization, especially in high-risk populations in Asia and beyond.”